Poorer patients with lung cancer less likely to receive treatment than wealtheir patients

February 8, 2013

Poorer lung cancer patients in the developed world are significantly less likely to receive treatment than richer patients, researchers from Newcastle University have found. This inequality in treatment may contribute to the higher death rates for lung cancer in poorer patients.

In a paper published today in the journal the authors found that this disparity could not be explained by differences in national healthcare systems or the stage at which cancer is diagnosed.

The team from Newcastle University and Fuse, the Centre for Translational Research in Public Health, analysed data from 46 previous studies from the UK and the US and also from Canada, Sweden, Australia, Italy, France, and New Zealand.

In their analysis, the authors found that patients with lung cancer who were from the lowest were 21 % less likely to receive any treatment than patients from the highest socioeconomic groups. Lower was also linked with a lower chance of receiving surgery (32% less likely) and chemotherapy (18% less likely), but not radiotherapy.

These findings are important as, in the UK and USA, lung cancer is the most common cause of and treatment with surgery, chemotherapy or radiotherapy improves in patients with lung cancer. A previous study in England and Wales has found that 1,300 deaths could be avoided if survival rates were the same as the highest socio-economic groups.

The authors also found that this link between socioeconomic position and receiving treatment was similar in studies from countries where healthcare is free for everyone (for example, in the UK) and in countries that have healthcare systems (for example, in the US). It is unclear at the moment what is driving these inequalities in receipt of treatment.

Lynne Forrest, lead author on the paper, said: "We were surprised that these inequalities remained even after we took account of the differences in healthcare system and in how advanced the cancer was at diagnosis.

"We do not know why this is happening, but we think it could be due to three possible factors. 

"Firstly co morbidity; poorer people may have other things wrong with them, making them unable to undergo aggressive cancer treatment.

"Secondly patient choice; poorer people may weigh up the benefits of treatment differently and therefore turn down the opportunity for treatment that could extend their life for a short while. There may be socioeconomic barriers to treatment uptake, such as access to transport, family circumstances, work flexibility and social support, that influence whether patients choose to undergo treatment.

"Thirdly, it may be that doctors are not communicating effectively with poorer or less well-educated patients. All of these factors will need to be looked at, as well as any others that we may uncover in future research."

Professor Martin White, Director of Fuse and study co-author added: "This is a serious public health concern that needs to be addressed. We are discovering that a range of health conditions are subject to inequalities in the way that healthcare is accessed and delivered. These can lead to unequal outcomes which may compound the already unequal distribution of diseases in the population."

Explore further: No therapy for 20 percent with stage IV solid tumors

More information: Reference: www.plosmedicine.org/article/i … journal.pmed.1001376

Related Stories

No therapy for 20 percent with stage IV solid tumors

June 23, 2012
(HealthDay) -- About 20 percent of patients diagnosed with stage IV metastatic solid tumors do not receive anticancer treatment, according to a study published online June 15 in Cancer.

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.